Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 5, 2007

Biotecnol Gained Access to PER.C6® for Antibody Production

  • Biotecnol obtained license rights to DSM Biologics’ and Crucell’s PER.C6® human cell line for preclinical and Phase I development of its antibody products, which are composed of Tribodies™ and compact antibodies.

    "We believe that by adopting the PER.C6 production platform, we will be able to develop our products in a robust, cost-efficient, and most importantly, in a timely way, due to its characteristics and ease of manipulation,” says Pedro de Noronha Pissarra, CEO of Biotecnol.

    Under the terms of the agreement, Biotecnol will make license payments and annual maintenance fees in exchange for certain rights.



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »